How THC Became an FDA-Approved Medicine for Chemotherapy Nausea
Decades before legal dispensaries, researchers tested standardized THC-like medicines for one of cancer treatment’s most miserable side effects.
The problem that pushed cannabinoid medicine forward
Before today’s strongest anti-nausea combinations, chemotherapy could cause repeated vomiting, dehydration, weight loss, and intense dread before the next treatment. Some people still had severe symptoms after the standard medicines available at the time. Researchers began testing whether THC’s effects on brain and gut signaling could provide another route to relief.
Patient experience became a research question
Reports that cannabis reduced nausea encouraged scientists to test measured THC and synthetic cannabinoid compounds rather than relying on variable smoked products.
Double-blind comparisons produced measurable results
Trials compared nabilone with established anti-nausea drugs. Benefits appeared in some patients, alongside frequent dizziness and drowsiness.
Prescription cannabinoids reached FDA approval
Marinol, containing dronabinol, and Cesamet, containing nabilone, were approved for chemotherapy-associated nausea and vomiting in patients who did not respond adequately to conventional treatment.
The role became more targeted
Modern antiemetics prevent most chemotherapy nausea more effectively and with less intoxication. Prescription cannabinoids remain options for refractory symptoms, chosen with the oncology team.
Six pieces of evidence behind the story
Nabilone helped some patients more than prochlorperazine
Eighteen patients had complete or partial symptom relief. Seven responded only to nabilone, three only to prochlorperazine, and eight to both. Drowsiness and dizziness were common with nabilone and limited dosing in one quarter of participants. Read the trial.
Vomiting episodes were lower with nabilone
Across two chemotherapy cycles, patients averaged 4.53 vomiting episodes with nabilone and 10.81 with domperidone. Subjective side effects were more frequent with nabilone, including sleepiness, dizziness, dry mouth, and blood-pressure drops when standing. Read the trial.
Cannabinoids worked, but tradeoffs were substantial
The review combined older trials of nabilone, dronabinol, and levonantradol against placebo or older antiemetics. Cannabinoids showed anti-nausea activity, while psychoactive and neurological side effects were more common. Read the review.
Dronabinol performed similarly to ondansetron for delayed symptoms
Total response was 54% with dronabinol, 58% with ondansetron, 47% with their combination, and 20% with placebo. The small sample and slow enrollment limit certainty. Read the study.
Potential value remained clearest for refractory nausea
The review concluded cannabis-based medicines may help when chemotherapy nausea and vomiting persist, but most trials were old, small, and conducted before current antiemetic regimens. Evidence quality was generally low. Read the review.
Standardized compounds became regulated medicines
The FDA recognizes dronabinol products Marinol and Syndros and the THC-like drug Cesamet for specific therapeutic uses, including chemotherapy nausea. Approval applies to those products and indications, not cannabis broadly. Read the FDA overview.
Where prescription cannabinoids fit today
Oncology has changed since the original cannabinoid trials. Modern combinations may include serotonin antagonists, NK1 antagonists, steroids, and other drugs chosen for the chemotherapy regimen. These are generally first-line because they are well studied and do not intentionally produce a high.
First priority
Prevent symptoms with the regimen recommended by the oncology team.
Rescue role
Consider dronabinol or nabilone when nausea persists despite appropriate conventional antiemetics.
Safety plan
Review sedation, dizziness, mental-health history, driving, falls, and interactions.
Why an approved THC medicine is different from smoking weed
Dronabinol has a known active ingredient and dose. Nabilone has a defined synthetic structure. Both have prescribing information, manufacturing standards, and monitored adverse effects. Cannabis flower varies by THC, CBD, terpenes, contaminants, and inhalation pattern. Smoke also adds airway irritants that an oral prescription does not.
Patients should tell the oncology team about any cannabis or cannabinoid use. THC can add to sleepiness, dizziness, confusion, blood-pressure changes, and impairment from other medicines. Cancer treatment decisions should never be delayed or replaced by cannabis.
Frequently asked questions
Is THC approved for chemotherapy nausea?
Prescription dronabinol and the THC-like medicine nabilone are FDA approved for chemotherapy-associated nausea and vomiting in specific circumstances, particularly after inadequate response to conventional antiemetics.
Are Marinol and THC the same?
Marinol contains dronabinol, a synthetic form of delta-9 THC. It is a standardized prescription capsule, not the same product as cannabis flower.
What is nabilone?
Nabilone is a synthetic cannabinoid with a structure similar to THC. It is sold as Cesamet for certain chemotherapy-related nausea and vomiting.
Do cannabinoid medicines replace modern anti-nausea drugs?
Usually no. Modern antiemetic combinations are standard first-line care. Cannabinoids are more often considered when symptoms remain difficult to control.
What side effects can occur?
Drowsiness, dizziness, dry mouth, mood or perception changes, confusion, impaired coordination, and blood-pressure changes can occur.
Can you drive after taking dronabinol or nabilone?
These medicines can impair judgment and coordination. Follow the prescribing instructions and do not drive or operate equipment while affected.
Does this mean cannabis treats cancer?
No. Controlling nausea is supportive care. It does not mean THC cures cancer or replaces chemotherapy, surgery, radiation, immunotherapy, or other cancer treatment.
Should a patient ask their oncologist about cannabis?
Yes. The oncology team can check interactions, local rules, symptom causes, and whether an approved prescription option is appropriate.
Research sources
Medical note: This story is educational and is not medical advice. Cancer patients should discuss nausea, vomiting, dehydration, weight loss, and cannabinoid use with their oncology team.
Chris Garcia, Owner and CEO
August 27, 2026
How this page is prepared: Plenny uses linked research and other relevant sources for educational explanations, and product details and batch COAs where relevant. General strain, flavor, and effect descriptions are not guarantees.
Commercial transparency: Plenny sells products discussed on this website. Educational pages are not medical or legal advice, and content is not medically reviewed unless a named licensed reviewer is shown.